RxDoctor Payments Data

Suparna Thind, MD

Nephrology · Fort Myers, FLNPI 1861838302

Payments from drug & device makers

$1,248in general payments, 2019–2025

Across 35 payments — averaging $35.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$532
  • Amgen$191
  • Akebia Therapeutics Inc$148
  • Bayer$68
  • Baxter Healthcare$65
  • Aurinia Pharma U.S., Inc.$61
  • plus $182 from 9 others

What the payments were for

  • Food & beverage$1,22898%
  • Education$202%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,248 in reported general payments places this provider in the 40th percentile of 756 nephrology providers in Florida.

See all nephrology providers in Florida

Medicare billing

Part B allowed, 2024
$246,260
Medicare patients
421
Services billed
2,096

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol82$75,579
KerendiaFinerenone20$30,741
LokelmaSodium Zirconium Cyclosilicate37$26,089
Cinacalcet Hcl24$21,490
JanuviaSitagliptin Phosphate15$18,600
Nicardipine Hcl12$15,326
Sevelamer Carbonate25$4,863
Torsemide140$2,641
Bumetanide64$2,487
Carvedilol236$2,412
Nifedipine ErNifedipine92$2,289
Calcitriol149$2,176
Allopurinol237$1,718
Calcium Acetate14$1,715
Hydralazine Hcl103$1,571

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$532$101,667119 claims
BayerKerendia$68$30,74120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 756 nephrology providers in Florida.

Other nephrology in Fort Myers

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →